Homologous and heterologous serological response to the N‐terminal domain of SARS‐CoV‐2 in humans and mice

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells

(2021) Shuai Wang et al.   CELL RESEARCH

Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody

(2021) C. Garrett Rappazzo et al.   SCIENCE

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

(2021) Jennifer M. Dan et al.   SCIENCE

Neutralizing antibody titres in SARS-CoV-2 infections

(2021) Eric H. Y. Lau et al.   Nature Communications

Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

(2021) Elizabeth M. Anderson et al.   CELL

Potent SARS-CoV-2 Neutralizing Antibodies Directed Against Spike N-Terminal Domain Target a Single Supersite

(2021) Gabriele Cerutti et al.   Cell Host & Microbe

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

(2021) Pengfei Wang et al.   NATURE

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

(2021) Zijun Wang et al.   NATURE

Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

(2021) Naveenchandra Suryadevara et al.   CELL

N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2

(2021) Matthew McCallum et al.   CELL

Structural basis for broad coronavirus neutralization

(2021) Maximilian M. Sauer et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

SARS-CoV-2 can recruit a haem metabolite to evade antibody immunity

(2021) Annachiara Rosa et al.   Science Advances

Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice

(2021) Tal Noy-Porat et al.   iScience

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

(2020) Alexandra C. Walls et al.   CELL

Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020

(2020) Ranawaka APM Perera et al.   Eurosurveillance

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody

(2020) Dora Pinto et al.   NATURE

Antibody responses to SARS-CoV-2 in patients with COVID-19

(2020) Quan-Xin Long et al.   NATURE MEDICINE

A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

(2020) Meng Yuan et al.   SCIENCE

A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS

(2020) Lianpan Dai et al.   CELL

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

(2020) Wanbo Tai et al.   CELL RESEARCH

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

(2020) Emilie Seydoux et al.   IMMUNITY

Viral dynamics in mild and severe cases of COVID-19

(2020) Yang Liu et al.   LANCET INFECTIOUS DISEASES

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

(2020) Lihong Liu et al.   NATURE

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2

(2020) Xiangyang Chi et al.   SCIENCE

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

(2020) Thomas F. Rogers et al.   SCIENCE

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

(2020) Philip J. M. Brouwer et al.   SCIENCE

Broad neutralization of SARS-related viruses by human monoclonal antibodies

(2020) Anna Z. Wec et al.   SCIENCE

SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses

(2020) He-wei Jiang et al.   Nature Communications

Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections

(2020) Huibin Lv et al.   Cell Reports

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients

(2020) Lakshmanane Premkumar et al.   Science Immunology

Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low Prevalence Communities and Reveal Durable Humoral Immunity.

(2020) Tyler J. Ripperger et al.   IMMUNITY

SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies

(2020) Christopher O. Barnes et al.   NATURE

A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge

(2020) Shipo Wu et al.   Nature Communications

From SARS to COVID-19: What lessons have we learned?

(2020) Qin Liu et al.   Journal of Infection and Public Health

Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement

(2020) Jinkai Zang et al.   Cell Discovery

Cross-Neutralization of a SARS-CoV-2 Antibody to a Functionally Conserved Site Is Mediated by Avidity

(2020) Hejun Liu et al.   IMMUNITY

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

(2020) Alicia T. Widge et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Origin and evolution of pathogenic coronaviruses

(2018) Jie Cui et al.   NATURE REVIEWS MICROBIOLOGY